Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a research note published on Saturday. The firm issued a sell rating on the biopharmaceutical company's stock.

LXRX has been the subject of a number of other research reports. Leerink Partners reissued a "market perform" rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Piper Sandler decreased their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Leerink Partnrs lowered Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $3.67.

Lexicon Pharmaceuticals Trading Down 2.0 %

NASDAQ LXRX traded down $0.01 on Friday, hitting $0.49. The company's stock had a trading volume of 9,847,964 shares, compared to its average volume of 6,275,788. The firm has a market cap of $120.88 million, a PE ratio of -0.65 and a beta of 1.02. The company's 50-day moving average is $0.53 and its 200 day moving average is $0.92. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. As a group, analysts predict that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. grew its position in Lexicon Pharmaceuticals by 630.7% during the fourth quarter. Point72 Asset Management L.P. now owns 8,988,421 shares of the biopharmaceutical company's stock valued at $6,638,000 after buying an additional 7,758,371 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in Lexicon Pharmaceuticals by 301.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock worth $5,582,000 after purchasing an additional 5,676,021 shares in the last quarter. Nantahala Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 186.6% in the fourth quarter. Nantahala Capital Management LLC now owns 6,604,150 shares of the biopharmaceutical company's stock worth $4,877,000 after buying an additional 4,300,000 shares in the last quarter. Tang Capital Management LLC boosted its position in shares of Lexicon Pharmaceuticals by 750.3% during the 4th quarter. Tang Capital Management LLC now owns 850,268 shares of the biopharmaceutical company's stock valued at $628,000 after acquiring an additional 750,268 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in Lexicon Pharmaceuticals during the fourth quarter valued at approximately $355,000. Institutional investors and hedge funds own 74.70% of the company's stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.